Comparison of mirtazapine and citalopram in the treatment of depression in patients with breast cancer

Comparison of the effectiveness of mirtazapine and citalopram on general health and quality of life in patients with major depression and breast cancer in the oncology ward

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220406054440N1

Enrollment

Registered

2022-05-10

Start date

2022-04-30

Completion date

Unknown

Last updated

2022-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depression, Breast Cancer, Mirtazapine, Citalopram. Malignant neoplasm of breast, major depression

Interventions

After the clinical interview, if there is a diagnosis of depression in the patient based on the DSM-V criteria, the patient enters the research project. After consultation with the hematology speciali

Eligibility

Sex/Gender

Female

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Females with breast cancer after radiotherapy surgery and undergoing chemotherapy or radiotherapy in stages 1 to 4 of disease progression Age over 18 years and under 65 years Middle school education level and higher Existence of major depression criteria based on DSM-V criteria

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Quality of life, general health. Timepoint: One and three months after starting treatment. Method of measurement: Questionnaire GHQ-28 and SF-36.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Zohreh Keyvanlou Shahrestanaki

Gorgan University of Medical Sciences

Dr.z.keyvanlou@gmail.com+98 17 3222 0561

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026